{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T17:19:08Z","timestamp":1783185548924,"version":"3.54.6"},"reference-count":9,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T00:00:00Z","timestamp":1776902400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002367","name":"Chinese Academy of Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002367","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013152","name":"Shanghai Institute of Materia Medica CAS","doi-asserted-by":"publisher","award":["SIMM0120231003"],"award-info":[{"award-number":["SIMM0120231003"]}],"id":[{"id":"10.13039\/501100013152","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Virus Research"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.virusres.2026.199733","type":"journal-article","created":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T23:00:24Z","timestamp":1776985224000},"page":"199733","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Deuremidevir hydrobromide (VV116) is a promising antiviral against human metapneumovirus"],"prefix":"10.1016","volume":"368","author":[{"given":"Huilong","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoli","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianwen","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanghui","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanchao","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingshan","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.virusres.2026.199733_bib0003","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s44162-025-00079-w","article-title":"Rising global threat of human metapneumovirus (hMPV in 2024\/2025): pathogenesis, immune dynamics, vulnerabilities in immunocompromised individuals, and lessons from past pandemics","volume":"4","author":"Adedokun","year":"2025","journal-title":"J. Rare Dis."},{"issue":"4","key":"10.1016\/j.virusres.2026.199733_bib0004","doi-asserted-by":"crossref","first-page":"667","DOI":"10.3390\/v13040667","article-title":"Broad-Spectrum Antiviral Strategies and Nucleoside Analogues","volume":"13","author":"Geraghty","year":"2021","journal-title":"Viruses"},{"issue":"12","key":"10.1016\/j.virusres.2026.199733_bib0007","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.3390\/v15122295","article-title":"Remdesivir derivative VV116 is a potential broad-spectrum inhibitor of both Human and animal coronaviruses","volume":"15","author":"Liu","year":"2023","journal-title":"Viruses"},{"issue":"3","key":"10.1016\/j.virusres.2026.199733_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.diagmicrobio.2025.116809","article-title":"Global impact of hMPV virus: transmission, pathogenesis, diagnostic and treatment","volume":"112","author":"Porwal","year":"2025","journal-title":"Diagn. Microbiol. Infect. Dis."},{"issue":"6","key":"10.1016\/j.virusres.2026.199733_bib0001","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/89098","article-title":"A newly discovered human pneumovirus isolated from young children with respiratory tract disease","volume":"7","author":"van den Hoogen","year":"2001","journal-title":"Nat. Med."},{"issue":"11","key":"10.1016\/j.virusres.2026.199733_bib0005","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1038\/s41422-021-00570-1","article-title":"Design and development of an oral remdesivir derivative VV116 against SARS-CoV-2","volume":"31","author":"Xie","year":"2021","journal-title":"Cell Res."},{"key":"10.1016\/j.virusres.2026.199733_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.virol.2024.110334","article-title":"The novel COVID-19 treatment VV116 is a potential inhibitor of Zika virus","volume":"603","author":"Yang","year":"2025","journal-title":"Virology"},{"issue":"1","key":"10.1016\/j.virusres.2026.199733_bib0006","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/s41392-022-00963-7","article-title":"Oral remdesivir derivative VV116 is a potent inhibitor of respiratory syncytial virus with efficacy in mouse model","volume":"7","author":"Zhang","year":"2022","journal-title":"Signal. Transduct. Target. Ther."},{"issue":"1","key":"10.1016\/j.virusres.2026.199733_bib0008","doi-asserted-by":"crossref","DOI":"10.1080\/22221751.2025.2587983","article-title":"The oral nucleoside drug VV116 is a promising candidate for treating Nipah virus infection","volume":"14","author":"Zhang","year":"2025","journal-title":"Emerg. Microbes. Infect."}],"container-title":["Virus Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168170226000523?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168170226000523?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T16:54:10Z","timestamp":1783184050000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168170226000523"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":9,"alternative-id":["S0168170226000523"],"URL":"https:\/\/doi.org\/10.1016\/j.virusres.2026.199733","relation":{},"ISSN":["0168-1702"],"issn-type":[{"value":"0168-1702","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Deuremidevir hydrobromide (VV116) is a promising antiviral against human metapneumovirus","name":"articletitle","label":"Article Title"},{"value":"Virus Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.virusres.2026.199733","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"199733"}}